Loading stock data…
$1.93-0.02 (-1.03%)
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally.
Fortress Biotech, Inc. in the Healthcare sector is trading at $1.92 with a market capitalization of $84M. Wall Street consensus targets $5.00 (1 analysts), implying a +161.1% move over the next 12 months. The stock is currently near its 52-week low of $1.88, remaining 34.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $18.72M↑ | $16.04M↓ | $16.08M↓ | $17.63M↑ | $16.41M |
| Gross Profit | $12.57M↑ | $9.82M↓ | $10.64M↓ | $11.88M↑ | $11.47M |
| Operating Income | -$10.01M↓ | -$7.74M↓ | -$4.79M↑ | -$6.81M↑ | -$36.47M |
| Net Income | -$468,000↓ | $110.37M↑ | -$3.94M↓ | $5.85M↓ | $15.49M |
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qb...